Are women living with HIV prone to osteoporosis in postmenopause? A systematic review
Carregando...
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2018
Editora
ASSOC MEDICA BRASILEIRA
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, v.64, n.5, p.469-473, 2018
Resumo
BACKGROUND: Some researchers have suggested that HIV infections can increase the cytokines, which might interfere with the bone metabolism and increase the risk of bone mass loss. However, this issue has yet to be consolidated in postmenopausal women. OBJECTIVE: To analyze studies that evaluated the loss of bone mass through DEXA in women living with HIV. MATERIALS AND METHODS: A systematic review was conducted following the PRISMA guideline. The MEDLINE, EMBASE and Cochrane databases were consulted from January 1987 to March 2017. Studies assessing bone mineral density (BMD) in postmenopausal women living with HIV were included. The secondary outcome was to evaluate the impact of antiretroviral on BMD. RESULTS: Sixty percent of the manuscripts suggested that women living with HIV had more bone loss than women in the control group, mainly in the lumbar spine. Forty percent did not observe any difference between groups. One study reported the influence of antiretroviral drugs on bone mass but did not find any difference between groups. CONCLUSION: Our data suggest that HIV infections may have a negative influence on bone mass loss in women. Further studies on the mechanism of this HIV consequence are necessary to clarify the connection as well as the impact of the antiretroviral action on BMD in postmenopausal women.
Palavras-chave
Climacteric, Osteoporosis, HIV, Bone Density
Referências
- ALEXEEVA L, 1994, WHO TECH REP SER, V843, P1
- Amiel C, 2004, J BONE MINER RES, V19, P402, DOI 10.1359/JBMR.0301246
- Arora Shitij, 2010, Curr Osteoporos Rep, V8, P219, DOI 10.1007/s11914-010-0036-x
- Aukrust P, 1999, J CLIN ENDOCR METAB, V84, P145, DOI 10.1210/jc.84.1.145
- Bolland MJ, 2007, J CLIN ENDOCR METAB, V92, P4522, DOI 10.1210/jc.2007-1660
- Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb
- Calmy A, 2013, OSTEOPOROSIS INT, V24, P1843, DOI 10.1007/s00198-012-2189-1
- Cao W, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20697
- Cazanave C, 2008, AIDS, V22, P395, DOI 10.1097/QAD.0b013e3282f423dd
- de Carvalho EH, 2010, ARQ BRAS ENDOCRINOL, V54, P133, DOI 10.1590/S0004-27302010000200008
- Dolan SE, 2004, AIDS, V18, P475, DOI 10.1097/00002030-200402200-00014
- Fonseca AM, 2010, DADOS DEMOGRAFICOS E, P23
- Grund B, 2009, AIDS, V23, P1519, DOI 10.1097/QAD.0b013e32832c1792
- Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
- Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135
- Serrano-Villar S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004078
- Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030-200003100-00005
- Teichmann J, 2003, J INFECTION, V46, P221, DOI 10.1053/jinf.2002.1109
- Ueland T, 2001, EUR J CLIN INVEST, V31, P72, DOI 10.1046/j.1365-2362.2001.00768.x
- Wells G, NEWCASTLE OTTAWA SCA
- Yin M, 2005, OSTEOPOROSIS INT, V16, P1345, DOI 10.1007/s00198-005-1845-0